Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01697969 · ClinicalTrials.gov registry record · Phase 4
Confocal Analysis of Corneal Structures of Symptomatic Allergic Conjunctivitis Patients
A Phase 4 study, sponsored by Alcon Research.
- Completed
- Registry status
- Phase 4
- Development phase
- 17
- Enrollment target
NCT01697969: Completed Phase 4 study, sponsored by Alcon Research.
NCT01697969 is a Phase 4 study that has completed, run by Alcon Research. The registered enrollment target is 17 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01697969, a Phase 4 study, has completed, sponsored by Alcon Research.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 17 participants
- Enrollment target
Study Summary
The purpose of this study is to descriptively evaluate the corneal structures of allergic conjunctivitis patients.
Primary Outcome
The patient rated the severity of ocular itching using a predetermined 0-4 scale, where 0=none and 4=severe itching with irresistible urge to rub. Each eye was rated separately. A 2-week washout period from prior allergy medication (if applicable) preceded the baseline assessment.
Interventions
- DRUG Olopatadine hydrochloride ophthalmic solution, 0.2%
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2012-09 |
| Est. Completion | 2013-07 |
| Phase | Phase 4 |
What the finished NCT01697969 record still lists
NCT01697969 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 17 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (97% lower).
The record links to 0 conditions, and to 1 intervention - of which Olopatadine hydrochloride ophthalmic solution, 0.2% is the first listed.
NCT01697969 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01697969 about?
NCT01697969 is a clinical study titled "Confocal Analysis of Corneal Structures of Symptomatic Allergic Conjunctivitis Patients". The purpose of this study is to descriptively evaluate the corneal structures of allergic conjunctivitis patients.
What is the current status of trial NCT01697969?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 17 participants. The study started on 2012-09. Estimated completion is 2013-07.
What interventions are being tested in trial NCT01697969?
The interventions under investigation include: Olopatadine hydrochloride ophthalmic solution, 0.2% (DRUG).
Who is sponsoring clinical trial NCT01697969?
This trial is sponsored by Alcon Research, which has 275 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01697969's enrollment target sits among peer trials
17 1854th of 2000 higher than 132 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02090140 · 17 participants · NA
Microfracture Versus Adipose Derived Stem Cells for the Treatment of Articular Cartilage Defects
- NCT03317860 · 17 participants · NA
Improving Measurement and Treatment of Post-stroke Neglect
- NCT04356469 · 17 participants · Phase 2
TCR Alpha Beta T-cell Depleted Haploidentical HCT in the Treatment of Non-Malignant Hematological Disorders in Children
- NCT04414046 · 17 participants · Phase 2
TCR Alpha Beta T-cell Depleted Haploidentical HCT in the Treatment of Primary Immunodeficiency and Inherited Metabolic Disorders in Children
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia